Correlates of Perceived Health-Related Quality of Life in Post-treatment Lyme Encephalopathy

Psychosomatics

Volumn 54, Issue 6, 2013, Pages 552-559

  Chandra, Avinash M ^a   Keilp, John G ^b   Fallon, Brian A ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; PLACEBO;

ADULT; ANXIETY; ARTICLE; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; FATIGUE; FEMALE; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HEALTH STATUS; HUMAN; LYME DISEASE; MALE; MEMORY DISORDER; MENTAL DISEASE; PAIN; POST TREATMENT LYME DISEASE SYNDROME; QUALITY OF LIFE; SELF REPORT; SHORT FORM 36; WESTERN BLOTTING;

ADULT; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; COGNITION; COGNITION DISORDERS; DEPRESSION; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; LINEAR MODELS; LYME NEUROBORRELIOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; RISK FACTORS; SYNDROME; TREATMENT OUTCOME;

EID: 84887612876     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2013.04.003     Document Type: Article

References (46)

1. Steere A.C. Lyme disease. N Engl J Med 2001, 345(2):115-125.
2. Shadick N.A., Phillips C.B., Sangha O., et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med 1999, 131(12):919-926.
3. Cairns V., Godwin J. Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 2005, 34(6):1340-1345.
4. Steere A.C., Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol 2004, 4(2):143-152.
5. Fallon B.A., Keilp J.G., Corbera K.M., et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008, 70(13):992-1003.
6. Centers for Disease Control and Prevention: Post-Treatment Lyme Disease Syndrome. Retrieved from 2013. http://www.cdc.gov/lyme/postLDS/index.html.
7. Yancey J.R., Thomas S.M. Chronic fatigue syndrome: diagnosis and treatment. Am Fam Physician 2012, 86(8):741-746.
8. Helfenstein M Jr, Goldenfum MA, Siena CA: Fibromyalgia: clinical and occupational aspects. Rev Assoc Med Bras 2012; 58(3):358-365.
9. Kaplan R.F., Meadows M.E., Vincent L.C., Logigian E.L., Steere A.C. Memory impairment and depression in patients with Lyme encephalopathy: comparison with fibromyalgia and nonpsychotically depressed patients. Neurology 1992, 42:1263-1267.
10. Gaudino E.A., Coyle P.K., Krupp L.B. Post-Lyme syndrome and chronic fatigue syndrome. Neuropsychiatric similarities and differences. Arch Neurol 1997, 54(11):1372-1376.
11. Keilp J.G., Corbera K.M., Slavov I., Taylor M.J., Sackeim H.A., Fallon B.A. WAIS-III and WMS-III performance in chronic Lyme disease. J Int Neuropsychol Soc 2006, 12(1):119-129.
12. Krupp L.B., Masur D., Schwartz J., et al. Cognitive functioning in late Lyme borreliosis. Arch Neurol 1991, 48(11):1125-1129.
13. Kaplan R.F., Trevino R.P., Johnson G.M., et al. Cognitive function in posttreatment Lyme disease: do additional antibiotics help?. Neurology 2003, 60(12):1916-1922.
14. Shadick N.A., Phillips C.V., Logigian E.L., et al. The long-term clinical outcomes of Lyme disease: a population-based retrospective cohort study. Ann Intern Med 1994, 121(8):560-567.
15. Schutzer S.E., Angel T.E., Liu T., et al. Distinct cerebrospinal fluid proteomes differentiate post-treatment Lyme disease from chronic fatigue syndrome. PLoS One 2011, 6(2):e17287.
16. Stricker R.B. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin Infect Dis 2007, 45(2):149-157.
17. Rupprecht T.A., Koedel U., Fingerle V., Pfister H.W. The pathogenesis of Lyme neuroborreliosis: from infection to inflammation. Mol Med 2008, 14(3-4):205-212.
18. Bockenstedt L.K., Gonzalez D.G., Haberman A.M., Belperron A.A. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest 2012, 122(7):2652-2660.
19. Klempner M.S., Hu L.T., Evans J., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001, 345(2):85-92.
20. Aucott J.N., Rebman A.W., Crowder L.A., Kortte K.B. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?. Qual Life Res 2013, 22(1):75-78.
21. Eikeland R., Mygland A., Herlofson K., Ljostad U. Risk factors for a non-favorable outcome after treated European neuroborreliosis. Acta Neurol Scand 2013, 127(3):154-160.
22. Fallon B.A., Nields J.A. Lyme disease: a neuropsychiatric illness. Am J Psychiatry 1994, 151(11):1571-1580.
23. Sackeim H.A., Keilp J.G., Rush A.J., et al. The effects of vagus nerve stimulation on cognitive performance in patients with treatment resistant depression. Neuropsychiatry Behav Neurol 2001, 14:53-56.
24. Keilp J.G., Sackheim H., Mann J.J. Correlates of trait impulsiveness in performance measures and neuropsychological tests. Psychiatry Res 2005, 135:191-201.
25. Beck A, Steer RA: Beck Depression Inventory Manual. San Antonio: Psychological corporation. 1987.
26. Zung W. A rating scale for anxiety disorders. Psychosomatics 1971, 12:371-379.
27. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46(10):1121-1123.
28. Melzack E. The short-form McGill pain questionnaires. Pain 1987, 30:191-197.
29. Ware J.E., Kosinski M., Keller S.D. SF-36 Physical and Mental Health Summary Scales: A User's Manual 1994, The Health Institute, Boston.
30. Ware J., Kosinski M. SF-36, Manual for Users, Version 1 1994, The Health Institute, Boston.
31. Bowerman B.L., O'Connell R.T. Linear Statistical Models: An Applied Approach 1990, Druxbury, Belmont, CA. 2nd ed.
32. Durbin J., Watson G.S. Testing for serial correlation in least squares regression, II. Biometrika 1951, 30(1-2):159-178.
33. Ware J.E. SF-36 health survey update. Spine 2000, 25(24):3130-3139.
34. Schwartz J.E., Jandorf L., Krupp L.B. The measurement of fatigue: a new instrument. J Psychosom Res 1993, 37(7):753-762.
35. Chandra A., Wormser G.P., Klempner M.S., et al. Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain Behav Immun 2010, 24(6):1018-1024.
36. Jacek E., Fallon B.A., Chandra A., Crow M.K., Wormser G.P., Alaedini A. Increased IFNα activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits. Neuroimmunology 2013, 255(1-2):85-91.
37. White P.D., Goldsmith K.A., Johnson A.L., et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011, 377(9768):823-836.
38. Rabkin J.G., McElhiney M.C., Rabkin R. Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics 2011, 52(4):328-336.
39. Wormser G.P., Dattwyler R.J., Shapiro E.D., et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43(9):1089-1134.
40. Halperin J.J., Shapiro E.D., Logigian E., et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007, 69(1):91-102.
41. Krupp L.B., Hyman L.G., Grimson R., et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003, 60(12):1923-1930.
42. Fallon B.A., Petkova E., Keilp J.G., Britton C.B. A reappraisal of the U.S. clinical trials of post-treatment Lyme disease syndrome. Open Neurol J 2012, 6:79-87.
43. Stricker R.B., Green C.L., Savely V.R., Chamallas S.N., Johnson L. Safety of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease. Minerva Med 2010, 101(1):1-7.
44. Hassett A.L., Radvanski D.C., Buyske S., et al. Role of psychiatric comorbidity in chronic Lyme disease. Arthritis Rheum 2008, 59(12):1742-1749.
45. Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16(9):606.
46. Hays RD: The Medical Outcomes Study (MOS) Measures of Patient Adherence. Retrieved from. 1994. http://www.rand.org/health/surveys/MOS.adherence.measures.pdf.